Corcept CFO sells 80,000 shares after option exercise
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Corcept Therapeutics Chief Financial Officer Mokari Atabak exercised stock options covering 80,000 shares of common stock at an exercise price of $23.06 per share on July 30, 2026, then sold 80,000 shares in multiple open-market or private transactions the same day.
The sales occurred at prices ranging from $105.305 to $120.84 per share. The option was fully exercisable and expires on February 13, 2033, with 95,833 options from this grant remaining. All reported sales were made under a Rule 10b5-1 trading plan adopted on December 12, 2025.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock option (right to buy) F14 | 80,000 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 80,000 | $23.06 | $1.84M |
| Sale | Common Stock F2, F3, F1 | 4,200 | $105.5352 | $443K |
| Sale | Common Stock F2, F4, F1 | 8,956 | $106.9553 | $958K |
| Sale | Common Stock F2, F1 | 400 | $108.46 | $43K |
| Sale | Common Stock F2, F5, F1 | 2,202 | $110.0283 | $242K |
| Sale | Common Stock F2, F1 | 600 | $110.95 | $67K |
| Sale | Common Stock F2, F6, F1 | 4,700 | $113.1789 | $532K |
| Sale | Common Stock F2, F7, F1 | 15,477 | $114.9601 | $1.78M |
| Sale | Common Stock F2, F8, F1 | 14,222 | $115.8669 | $1.65M |
| Sale | Common Stock F2, F9, F1 | 7,089 | $116.9561 | $829K |
| Sale | Common Stock F2, F10, F1 | 8,267 | $117.9329 | $975K |
| Sale | Common Stock F2, F11, F1 | 4,783 | $118.7346 | $568K |
| Sale | Common Stock F2, F12, F1 | 8,103 | $119.9481 | $972K |
| Sale | Common Stock F2, F13, F1 | 1,001 | $120.6749 | $121K |
Footnotes (14)
- F1. Includes 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 397 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
- F2. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 12, 2025 in effect at the time of this transaction.
- F3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $105.305 to $106.2 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F4. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $106.75 to $107.195 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F5. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $109.71 to $110.42 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F6. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.96 to $113.89 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F7. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.305 to $115.30 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F8. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.35 to $116.27 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F9. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.35 to $117.3 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F10. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $117.41 to $118.39 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F11. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $118.42 to $119.21 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F12. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $119.42 to $120.41 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F13. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $120.49 to $120.84 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F14. Fully exercisable.
Key Figures
Key Terms
Rule 10b5-1 plan regulatory
weighted average sale price financial
restricted stock awards financial
stock option (right to buy) financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Corcept Therapeutics (CORT) CFO Mokari Atabak report?
What stock options did the Corcept (CORT) CFO exercise in this report?
What restricted stock awards are referenced for the Corcept (CORT) CFO?
What is the remaining option position after the Corcept (CORT) CFO’s exercise?
AI-generated analysis. How Rhea-AI works. Not financial advice.